This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Online Education Stocks to Buy as Coronavirus Fears Rise
by Ritujay Ghosh
The COVID-19 pandemic has completely changed the concept of learning, which has led to the popularity of online education stocks like American Public Education, Inc. (APEI), GP Strategies Corporation (GPX) and Lincoln Educational Services Corporation (LINC).
Bull of the Day: Quidel (QDEL)
by Kevin Cook
COVID and influenza A+B tests have launched sales and profit estimates triple-digits into 2021
Inflation to Pick Up in 2021: Bet on TIPS ETFs
by Sweta Killa
The expectation for an uptick in inflation has led to investors' flocking to Treasury Inflation Protected Securities (TIPS) ETFs.
Emerging Markets Hit Record High: 5 Top-Performing ETFs YTD
by Sweta Killa
While many emerging market ETFs have been performing remarkably well, we highlight five funds that are leading the space from a year-to-date basis.
Pfizer/BioNTech COVID-19 Vaccine Raises New Safety Concerns
by Zacks Equity Research
The Bell's palsy related side-effects are not alarming enough to preclude FDA from granting emergency approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine.
5 Sector ETFs Still At Cheap Prices Amid Peak Market
by Sweta Killa
Though many sectors are hitting new highs amid the peak market, some funds are still down from a year-to-date look and are due to climb in the coming weeks.
Stock Market News for Dec 10, 2020
by Zacks Equity Research
Markets ended lower on Wednesday as tech stocks took a hit and investors grew impatient over the prospects of a fresh round of fiscal stimulus.
Vaccine Euphoria Aids Oil in the Face of Huge Supply Build
by Nilanjan Choudhury
The top gainers of the S&P 500 during the past month are all energy firms - Occidental Petroleum (OXY), Apache (APA), Diamondback Energy (FANG), Marathon Oil (MRO) and Devon Energy (DVN).
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $41.85, marking a -1.67% move from the previous day.
Markets Book Profits as Vaccine Rally Stalls; DASH Jumps 86% on IPO
by Mark Vickery
DoorDash (DASH) shares closed its first day on the New York Stock Exchange at $189 per share.
Roche (RHHBY), Moderna Ink Deal for Coronavirus Antibody Test
by Zacks Equity Research
Roche (RHHBY) partners with Moderna to allow the latter utilize its Elecsys Anti-SARS-CoV-2 S antibody test in the mRNA-1273 vaccine research studies.
Micron Technology, RCI Hospitality, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Micron Technology, RCI Hospitality, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day
Equal-Weight ETFs Leading Latest Market Rally: Here's Why
by Sweta Killa
While the rally has been broad-based, equal-weighted ETFs are outperforming their cap-weighted peers.
IPO Market Set to Thrive in December
by Zacks Equity Research
IPO Market Set to Thrive in December
DoorDash IPOs at $102, Vaccine Rally Cooling
by Mark Vickery
DoorDash is pricing its Initial Public Offering at $102 per share, for a valuation of $38.7 billion.
Leveraged ETFs to Tap as S&P 500 Tops 3700 Mark
by Sweta Killa
The enthusiasm surrounding the rollout of Pfizer's (PFE) vaccine has spurred a strong wave of bullishness.
Stock Market News for Dec 9, 2020
by Zacks Equity Research
U.S. stocks closed higher on Tuesday as investors¿¿¿ sentiment got a boost from positive news on the COVID-19 vaccine front that overshadowed worries of surging coronavirus cases and a record number of hospitalizations, and slow progress in the sanction of another financial aid.
Pfizer (PFE) Pneumococcal Vaccine BLA Gets FDA's Priority Tag
by Zacks Equity Research
Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine candidate helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.
S&P 500 Momentum to Continue on Stimulus Hopes: 4 Picks
by Aniruddha Ganguly
Here we pick four S&P 500 stocks -- LB, HOLX, MU & TGT -- that have strong growth prospects driven by the rising stimulus hopes and vaccine approvals.
5 Materials Stocks to Make the Most of Economic Recovery
by Zacks Equity Research
U.S. economy is poised for a rebound on positive COVID-19 vaccine developments and hopes of a fiscal stimulus, making it prudent to invest in stocks like Bunge (BG) and Cabot (CBT) from the materials sector.
Next Chapter in Covid-19 Era Underway
by Mark Vickery
Aside from sub-zero refrigeration requirements, the Pfizer-BioNTech vaccine looks to be first in line and among the highest efficacy rates possible.
Should You Buy Oil & Gas ETFs Now?
by Neena Mishra
Energy ETFs rebounded strongly in November but are still down significantly for the year
Productivity Increases in Q3
by Zacks Equity Research
Productivity Increases in Q3
Moderna (MRNA) to Supply More Doses of COVID-19 Vaccine to Canada
by Zacks Equity Research
Moderna (MRNA) announces deal to supply 20 million additional doses of its COVID-19 vaccine candidate, mRNA-1273, to the Canadian Government, upon potential approval. The total tally is now 40 million doses.
Markets Find Vaccine-Rally Equilibrium; AZO Mixed in Q1
by Mark Vickery
Great Britain injects its first Pfizer (PFE)-BioNTech (BNTX) vaccine patients today, marking a momentous occasion whereby the world may soon return to pre-pandemic activities.